A Pivotal, Single-Dose, Randomised, Parallel-Group, Open-Label Study to Demonstrate Bioequivalence of 250mg Lamotrigine XR Relative to 200mg + 50mg Lamotrigine XR and to Demonstrate Lack of Food Effect on 250mg Lamotrigine XR in Healthy Male and Female Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Lamotrigine (Primary)
- Indications Epilepsy; Lennox-Gastaut syndrome; Mood disorders
- Focus Pharmacokinetics; Registrational
- Sponsors GlaxoSmithKline
- 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2008 New trial record.